Drug intelligence / Profile preview

SUN13834

Development stage: Phase 2
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral

Overview

SUN13834 is a novel, orally administered small molecule chymase inhibitor developed by Asubio Pharma and Daiichi Sankyo for the treatment of atopic dermatitis. Chymase is a chymotrypsin-like serine protease stored in mast cell granules and implicated in allergic diseases and skin inflammation. Preclinical studies demonstrated that SUN13834 ameliorates skin inflammation and pruritus in animal models of atopic dermatitis by inhibiting mast cell chymase activity, reducing inflammatory cell accumulation, and decreasing scratching behavior. Clinical development reached phase 2 trials for atopic dermatitis but was discontinued before approval.

Other names: INVA8001INVA-8001INVA 8001ASB-17061ASB17061ASB 17061

Targets

CMA1 (Chymase)

Beyond the preview

Go deeper on SUN13834.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUN13834.

Explore the full profile